VIDEO: PET-guided strategy improves safety of advanced Hodgkin lymphoma treatment
Click Here to Manage Email Alerts
PET-guided strategy improved the safety of BEACOPP-based treatment in advanced Hodgkin lymphoma, according to prolonged follow-up data from the AHL 2011 phase 3 study presented at the ASH Annual Meeting and Exposition.
“I think this is probably the best data that we have in advanced-stage Hodgkin lymphoma,” Ann S. LaCasce, MD, MSc, of Dana-Farber Cancer Institute, told Healio in a video interview.
LaCasce also discussed the promise of new agents in Hodgkin lymphoma.
“The biology is so fascinating, and we have dissected out some of these mechanisms in such an elegant way that have really changed how we think about this disease,” LaCasce said. “It’s a rare disease, but it effects a lot of young adults, so it is such an important disease to manage in a way that’s going to essentially cure the most patients with as little late toxicity as possible. I think by having all these new agents hopefully we’ll use less radiation and drugs ... that may have late toxicity.”
Collapse
Casasnovas O, et al. Abstract 475. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about
Click Here to Manage Email Alerts